SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The $RAGE community is driving momentum by promoting the restoration of iconic, early-2000s era internet meme generators and tools on the Solana blockchain. Supporters are actively engaging in 'bagworking' and meme creation to build long-term conviction, positioning the project as a foundational 'OG' meme asset.

Maul Coin

Maul Coin is driving significant community engagement as holders rally behind an active developer to push for organic growth, increased visibility on trading platforms, and a long-term vision of sustained market cap expansion. The conversation is currently dominated by enthusiasts coordinating raids and social media activity to fuel a potential breakout, while simultaneously addressing skepticism from market critics.

Dunald Dump

The community is actively discussing the rapid momentum and viral potential surrounding this new meme coin, focusing on its market capitalization growth and speculative entry opportunities.

Bitcoin SV (BSV) emerged following a hard fork of the Bitcoin Cash (BCH) blockchain in 2018, which had in turn forked from the BTC blockchain a year earlier. The goal of Bitcoin SV is to fulfil the original vision of the Bitcoin protocol and design as described in Satoshi Nakamoto’s white paper, early Bitcoin client software and known Satoshi writings. BSV aims to offer scalability and stability in line with the original description of Bitcoin as a peer-to-peer electronic cash system, as well as deliver a distributed data network that can support enterprise-level advanced blockchain applications. To this end, it has removed artificial block size limits and re-enabled Script commands and other technical capabilities which had been historically disabled or restricted by the protocol developers of the BTC blockchain. This allows the network to process tens of thousands of transactions per second while maintaining extremely low transaction fees for micropayments, in addition to offering advanced capabilities such as tokens, smart contracts, computation and other data use cases. The BSV network is unique in its capacity for unbounded on-chain scaling while also being more aligned with the original design of Bitcoin than any other blockchain.

Bitcoin SV

Bitcoin SV is currently generating intense community debate as participants weigh the implications of the ongoing legal challenges regarding Craig Wright's identity and his association with the project. While some investors remain focused on the potential of the network's high transaction capacity and its original white paper design, others are actively reacting to price volatility and the broader sentiment surrounding the asset's delisting from major platforms.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as community members highlight its low market cap and ultra-limited circulating supply as potential catalysts for significant upside. Traders are actively debating the token's long-term potential compared to other projects, with many focused on accumulation and the impact that increased trading volume could have on its price action.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as investors react to its new payroll infrastructure integration with the Stellar network, fueling community speculation about a potential future partnership with Ripple. While holders remain focused on the project's real-world utility and long-term staking potential, the stock is experiencing significant volatility as market participants debate whether these announcements represent a lasting catalyst or a temporary pump.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending as the community closely watches for upcoming earnings and potential catalysts, with active debate focusing on heavy call option volume, high short interest, and persistent rumors of a potential merger or acquisition. Traders remain divided, with some positioning for a short squeeze fueled by significant institutional partnerships, while others express caution due to ongoing concerns regarding recent leadership transitions and execution.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major point of discussion due to a mix of aggressive community speculation regarding a potential recovery and significant debate over recent leadership shifts within the foundation. Traders are actively analyzing the token's technical positioning and its long-term viability, with many members emphasizing the network's quantum-resistant architecture and ongoing institutional adoption as catalysts for a future rebound.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and community division as traders weigh historically high valuations against continued AI infrastructure demand. While some investors are betting on further upside through aggressive call buying, others are warning of a crowded trade and potential bubble risks, fueling a debate over whether the sector is poised for a major correction or further growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Asian ETFs in Jeopardy Amid the War & Tariff Double Whammy?

Asian ETFs are under pressure as surging oil prices and new U.S. tariffs trigger market turmoil and sharp fund outflows across the region.

Legend Biotech Corp. (LEGN) is reportedly considering a second listing outside of the US.According to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us">report</a> on Friday, which cited unnamed people familiar with the matter, the New Jersey-headquartered company has discussed a second listing option with potential advisers. The company may list in Hong Kong, Singapore, or London, the report stated, while noting that a second listing could help boost the company's valuation, particularly if in Hong Kong.Hong Kong is currently emerging as a hub for biotech company listing, and the city’s Hang Seng Biotech Index has surged more than 100% this year, the report added.However, the company is only considering a second listing and may eventually decide against it, sources told Bloomberg.<a href="https://stocktwits.com/symbol/LEGN">LEGN shares</a> traded 3% higher at the time of writing. On Stocktwits, retail sentiment around LEGN stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.In August, Legend reported second-quarter (Q2) adjusted net income of $10.1 million, compared to an adjusted net loss of $2.5 million for the three months ended June 30, 2024, and total revenue of $255.1 million. The company ended June with cash and cash equivalents, as well as time deposits, totaling $1 billion.Legend, founded in 2014, is centered in the U.S. despite having roots in China and employs over 2,800 people. It's known for Carvykti, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets in collaboration with Johnson &amp; Johnson.LEGN stock is up 11% this year but down approximately 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/immunome-stock-rises-after-craig-hellum-initiates-coverage-with-26-dollar-price-target/chwIWHxRdqE">Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Legend Biotech Considering Second Listing Outside US: Report

According to a Bloomberg report, the New Jersey-based company has discussed the option with potential advisers.

Equity

iShares Trust - iShares MSCI All Country Asia ex Japan ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$96.11
Prev Close	$97.19
Open	$94.46
Dividend Yield	N/A
50-Day Moving Average	$100.61
Beta	N/A
Avg. Volume	1.72M
PE Ratio	N/A

52-Week High	$107.85
52-Week Low	$64.33
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

AAXJ
iShares MSCI All Country Asia ex-Japan ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AAXJ News

AAXJiShares MSCI All Country Asia ex-Japan ETF